Celltrion To Invest $478 M to Expand Former Lilly US Mfg Plant
By
Celltrion Group, an Incheon, South Korea-based bio/pharmaceutical company, has announced plans to invest KRW 700 billion ($478 million) to expand a former Lilly active pharmaceutical ingredient (API) manufacturing facility in the US. Celltrion completed the acquisition of…
